Clinical Trial Detail

NCT ID NCT04149821
Title Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Weill Medical College of Cornell University
Indications

chronic lymphocytic leukemia

Therapies

Ublituximab + Umbralisib

Age Groups: adult senior

No variant requirements are available.